Nektar Therapeutics Reports Second Quarter 2023 Financial Results

Rhea-AI Summary

Nasdaq: NKTR - Nektar Therapeutics reports Q2 2023 financial results with $409.4 million in cash and securities, plans for rezpegaldesleukin Phase 2b study and IND filing in 2024. Revenue decreased to $20.5 million in Q2 2023. Operating costs and expenses decreased in Q2 and first half of 2023 due to lower R&D and G&A expenses, as well as restructuring and impairment costs. Net loss for Q2 2023 was $51.1 million, improved from $159.1 million in Q2 2022. Nektar announced promising new rezpegaldesleukin data and continues cost reduction initiatives and strategic partnerships evaluation.

Positive

• Nektar Therapeutics has $409.4 million in cash and marketable securities, providing financial stability for strategic development activities and operations until at least mid-2026.
• The company plans to initiate a Phase 2b study of rezpegaldesleukin in patients with atopic dermatitis and aims to have initial data from this study in the first half of 2025. Additionally, Nektar is working on advancing its next pipeline candidates in immunology with an IND filing in 2024.
• Operating costs and expenses decreased in Q2 and first half of 2023 due to lower R&D and G&A expenses, as well as restructuring and impairment costs.
• Net loss for Q2 2023 was $51.1 million, improved from $159.1 million in Q2 2022.
• Nektar announced promising new rezpegaldesleukin data and continues cost reduction initiatives and strategic partnerships evaluation.

Negative

• None.

SAN FRANCISCO, Aug. 8, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023.

Cash and investments in marketable securities at June 30, 2023, were $409.4 million as compared to $505.0 million at December 31, 2022. Nektar's cash and marketable securities are expected to support strategic development activities and operations into at least the middle of 2026.

"With new and corrected strong clinical data for REZPEG, we look forward to initiating a Phase 2b study of rezpegaldesleukin in patients with atopic dermatitis and achieving our objective to have initial data from this study in the first half of 2025," said Howard W. Robin, President and CEO of Nektar. "We also are working to advance our next pipeline candidates in immunology with an IND filing in 2024. And finally, we are continuing our Phase 2 studies of NKTR-255 in liquid and solid tumors as we evaluate strategic partnership pathways."

Summary of Financial Results

Revenue in the second quarter of 2023 was $20.5 million as compared to $21.6 million in the second quarter of 2022. Revenue for the first half of 2023 was $42.1 million as compared to $46.4 million in the first half of 2022.

Total operating costs and expenses in the second quarter of 2023 were $71.1 million as compared to $174.4 million in the second quarter of 2022. Total operating costs and expenses in the first half of 2023 were $227.4 million as compared to $315.8 million in the first half of 2022. Operating costs and expenses for both the second quarter and first half of 2023 decreased due to decreases in research and development expense, general and administrative expense and restructuring, impairment and costs of terminated program. For the first half of 2023, these decreases were partially offset by $76.5 million in non-cash goodwill impairment and $26.5 million in other non-cash impairment charges primarily related to lease assets.

R&D expense in the second quarter of 2023 was $29.7 million as compared to $42.7 million for the second quarter of 2022. For the first half of 2023, R&D expense was $60.2 million as compared to $150.0 million in the first half of 2022. R&D expense decreased for both the second quarter and first half of 2023 due to due to the wind down of the bempegaldesleukin program.

G&A expense was $17.9 million in the second quarter of 2023 as compared to $20.5 million in the second quarter of 2022. For the first half of 2023, G&A expense was $39.0 million as compared to $47.9 million in the first half of 2022. G&A expense decreased for both the second quarter and first half of 2023 due to the wind down of the bempegaldesleukin program.

Restructuring, impairment and costs of terminated program were $16.6 million in the second quarter of 2023 as compared to $106.0 million in the second quarter of 2022. The amount for the second quarter of 2023 includes $13.3 million in non-cash lease impairment charges, $1.9 million in severance, and $1.4 million for the wind down of the bempegaldesleukin program. The amount for the second quarter of 2022 includes $57.3 million in non-cash lease and equipment impairment charges, $27.8 million in severance and $20.4 million for the wind down of the bempegaldesleukin program.

For the first half of 2023, restructuring, impairment and costs of terminated program were $37.7 million. This amount includes $26.5 million in non-cash lease and equipment impairment charges, $7.4 million in severance and $3.0 million for the wind down of the bempegaldesleukin program. The amounts for the first half of 2022 are consistent with the amounts for the second quarter of 2022.

Net loss for the second quarter of 2023 was $51.1 million or $0.27 basic and diluted loss per share as compared to a net loss of $159.1 million or $0.85 basic and diluted loss per share in the second quarter of 2022. Net loss in the first half of 2023 was $188.1 million or $0.99 basic and diluted loss per share as compared to a net loss of $249.5 million or $1.34 basic and diluted loss per share in the first half of 2022. Excluding the $103.0 million in non-cash goodwill and other impairment charges, net loss, on a non-GAAP basis for the first half of 2023 was $85.1 million or $0.45 basic and diluted loss per share.

Second Quarter 2023 and Recent Business Updates

• Nektar announced promising new and corrected rezpegaldesleukin efficacy data which were previously reported in 2022 and inaccurately calculated by former collaborator Eli Lilly & Co.
• Nektar continues to execute on several cost reduction initiatives as announced in its strategic reprioritization and cost restructuring plan in April 2023.
• Nektar continues to evaluate strategic partnership options for NKTR-255, the Company's lead oncology asset, while the Phase 2 study of NKTR-255 in combination with cell therapies and the Phase 2 JAVELIN Bladder Medley Study with partner Merck KGaA progress.

Conference Call to Discuss Second Quarter 2023 Financial Results

Nektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time, August 8, 2023.

This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through September 8, 2023.

To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in immunology and oncology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional manufacturing operations in Huntsville, Alabama. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements which can be identified by words such as: "will," "may," "advance," "support," "develop," "provide," "expect," "aim," "potential" and similar references to future periods. Examples of forward-looking statements include, among others, statements regarding the therapeutic potential of, and future development plans for rezpegaldesleukin, NKTR-255 and our other drug candidates in research programs, the prospects and plans for our collaborations with other companies, the timing of the initiation of clinical studies and the data readouts for our drug candidates, and our expected working capital and cash runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements regarding the therapeutic potential of rezpegaldesleukin, NKTR-255 and our other drug candidates are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin, NKTR-255 and our other drug candidates are investigational agents and continued research and development for these drug candidates is subject to substantial risks, including negative safety and efficacy findings in ongoing clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (iii) rezpegaldesleukin, NKTR-255 and our other drug candidates are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval; (iv) the timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to challenges caused by the COVID-19 pandemic, regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (v) we may not achieve the expected cost savings we expect from our 2022 corporate restructuring and reorganization plan or our 2023 cost restructuring plan and we may undertake additional restructuring and cost-saving activities in the future, (vi) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vii) certain other important risks and uncertainties set forth in our Annual Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2023. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:

For Investors:

Vivian Wu of Nektar Therapeutics
628-895-0661

For Media:

David Rosen of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com

NEKTAR THERAPEUTICS
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)
ASSETS				June 30, 2023		December 31, 2022	(1)
Current assets:
	Cash and cash equivalents			$                     50,728		$                      88,227
	Short-term investments			358,704		416,750
	Accounts receivable			1,335		5,981
	Inventory, net			20,689		19,202
	Other current assets			9,602		15,808
		Total current assets		441,058		545,968
Property, plant and equipment, net				22,554		32,451
Operating lease right-of-use assets				29,015		53,435
Goodwill				-		76,501
Other assets				1,652		2,245
		Total assets		$                   494,279		$                    710,600
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
	Accounts payable			$                        2,619		$                      12,980
	Accrued expenses			29,142		36,557
	Operating lease liabilities, current portion			18,933		18,667
		Total current liabilities		50,694		68,204
Operating lease liabilities, less current portion				105,817		112,829
Liabilities related to the sales of future royalties, net				135,659		155,378
Other long-term liabilities				5,151		7,551
		Total liabilities		297,321		343,962
Commitments and contingencies
Stockholders' equity:
	Preferred stock			-		-
	Common stock			19		19
	Capital in excess of par value			3,592,722		3,574,719
	Accumulated other comprehensive loss			(6,450)		(6,907)
	Accumulated deficit			(3,389,333)		(3,201,193)
		Total stockholders' equity		196,958		366,638
	Total liabilities and stockholders' equity			$                   494,279		$                    710,600

(1) The consolidated balance sheet at December 31, 2022 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements.

 

NEKTAR THERAPEUTICS
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share information)
(Unaudited)
			Three months ended June 30,				Six months ended June 30,
			2023		2022		2023		2022
Revenue:
	Product sales		$                        4,658		$                        5,312		$                        9,376		$                      11,000
	Non-cash royalty revenue related to the sales of future royalties		15,832		16,264		32,693		33,825
	License, collaboration and other revenue		9		9		24		1,582
Total revenue			20,499		21,585		42,093		46,407
Operating costs and expenses:
	Cost of goods sold		6,994		5,115		14,054		10,430
	Research and development		29,681		42,740		60,150		149,993
	General and administrative		17,869		20,521		38,950		47,860
	Restructuring, impairment, and costs of terminated program		16,554		106,045		37,747		107,520
	Impairment of goodwill		-		-		76,501		-
Total operating costs and expenses			71,098		174,421		227,402		315,803
	Loss from operations		(50,599)		(152,836)		(185,309)		(269,396)
Non-operating income (expense):
	Change in fair value of development derivative liability		-		-		-		33,427
	Non-cash interest expense on liabilities related to the sales of future royalties		(6,152)		(7,228)		(12,557)		(14,757)
	Interest income and other income (expense), net		5,582		1,096		9,616		1,491
Total non-operating income (expense), net			(570)		(6,132)		(2,941)		20,161
Loss before provision for income taxes			(51,169)		(158,968)		(188,250)		(249,235)
Provision (benefit) for income taxes			(47)		100		(110)		226
Net loss			$                    (51,122)		$                  (159,068)		$                  (188,140)		$                  (249,461)
Basic and diluted net loss per share			$                        (0.27)		$                         (0.85)		$                        (0.99)		$                         (1.34)
Weighted average shares outstanding used in computing basic and diluted net loss per share			189,656		186,800		189,268		186,323

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-reports-second-quarter-2023-financial-results-301896193.html

SOURCE Nektar Therapeutics

FAQ

What are Nektar Therapeutics' financial results for Q2 2023?

Nektar reported $409.4 million in cash and marketable securities at the end of Q2 2023, supporting strategic development activities and operations until at least mid-2026. Revenue decreased to $20.5 million in Q2 2023.

What are Nektar Therapeutics' plans for rezpegaldesleukin?

Nektar plans to initiate a Phase 2b study of rezpegaldesleukin in patients with atopic dermatitis and aims to have initial data from this study in the first half of 2025.

How did Nektar Therapeutics' operating costs and expenses change in Q2 and first half of 2023?

Operating costs and expenses decreased in Q2 and first half of 2023 due to lower R&D and G&A expenses, as well as restructuring and impairment costs.

What was Nektar Therapeutics' net loss for Q2 2023?

Net loss for Q2 2023 was $51.1 million, improved from $159.1 million in Q2 2022.

What recent business updates did Nektar Therapeutics announce?

Nektar announced promising new rezpegaldesleukin data and continues cost reduction initiatives and strategic partnerships evaluation.